Welcome to our dedicated page for Medicinova SEC filings (Ticker: MNOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MediciNova, Inc. filings document a clinical-stage biopharmaceutical issuer developing MN-166 and MN-001 across neurological, inflammatory, fibrotic, and metabolic disease programs. Annual and event filings describe reported financial results, including preliminary unaudited results furnished through a Japanese Kessan Tanshin, and securities registration materials for common stock offerings.
Proxy and 8-K filings cover MediciNova's Delaware corporate governance, director elections, executive compensation, equity awards, stockholder voting results, and Nasdaq-listed common stock. The filing record also provides formal disclosure around capital structure, risk factors, material events, and governance matters tied to the company's drug-development business.
MediciNova, Inc. (MNOV) files an S-1 describing its clinical-stage pipeline centered on MN-166 (ibudilast) and MN-001 (tipelukast) and a financing arrangement with YA. MN-166 showed positive Phase 2b SPRINT-MS results including a 48% reduction in whole brain atrophy versus placebo (p=0.04) and a 26% reduction in risk of confirmed disability progression (HR=0.74); results were published in the New England Journal of Medicine. Multiple additional MN-166 programs reported milestones: positive Phase 2 COVID-19 ARDS topline results (statistical significance on respiratory-failure-free and hospital discharge endpoints; two placebo deaths, none on drug), IND and Orphan Drug for glioblastoma with Phase 2 enrollment completed, and ongoing/additional addiction and ophthalmic studies. MN-001 holds Fast Track designation for NASH with fibrosis and has completed/initiated several Phase 2 studies with positive subgroup and preclinical findings.
On financing, the company may sell up to $30.0 million of common stock to YA under a Purchase Agreement (registration to cover up to 25,000,000 shares). If all 25,000,000 shares were outstanding, they would represent ~51.0% of total shares and ~52.5% of non-affiliate shares (as of Aug 11, 2025). The agreement also includes an Exchange Cap limiting issuance to 9,804,345 shares (~19.99%) absent shareholder approval or price conditions. The filing lists exhibits, prior SEC filings, and signatures.
Medicinova, Inc. reports key disclosures including business risks, capital structure, segment reporting and recent lease and equity arrangements. The company lists numerous risk factors such as inability to raise capital, failure to generate product revenues, clinical trial delays or failures, reliance on its MN-166 (ibudilast) and MN-001 (tipelukast) product candidates, dependence on third parties for trials, manufacturing and commercialization, intellectual property disputes, and international and regulatory risks. Common stock authorized is 100,000,000 shares with 49,046,246 shares issued and outstanding at June 30, 2025 and December 31, 2024. The CODM evaluates performance using consolidated net loss and functional expenses. The company amended its Tokyo office lease to a 14-month term for measurement purposes using a 6.51% incremental borrowing rate. There were 970,000 performance options outstanding tied to 2025 objectives and Black-Scholes inputs are disclosed. An equity sale agreement pays 3.5% of gross proceeds to the agent. The company states strategic priorities to develop MN-166 and MN-001 and pursue non-dilutive financing and partnerships.
Form 4 filed for Medicinova, Inc. (MNOV) discloses that director Hideki Nagao received an option grant for 20,000 shares of common stock on 16 June 2025 at an exercise price of $1.26 per share. The options expire on 16 June 2035 and vest in four equal tranches on 30 Sep 2025, 31 Dec 2025, 31 Mar 2026 and 30 Jun 2026, contingent upon continued board service. No shares were sold or otherwise disposed of, and Nagao’s beneficial ownership in derivative securities increases to 20,000 options following this single transaction. The filing represents routine equity-based compensation and does not indicate any change in company fundamentals or insider sentiment beyond standard alignment incentives.
Medicinova, Inc. (MNOV) – Form 4 insider filing
On 17 June 2025, director Carolyn Beaver was granted an option to purchase 20,000 shares of Medicinova common stock. The option’s exercise price is $1.26 per share and it will expire on 16 June 2035.
The award vests in four equal installments of 5,000 shares on the following dates, contingent on continued board service:
- 30 Sep 2025
- 31 Dec 2025
- 31 Mar 2026
- 30 Jun 2026
Following this grant, Beaver reports beneficial ownership of 20,000 derivative securities and no change in non-derivative holdings was disclosed.
The transaction was coded “A” (grant) and filed as a single-reporting-person Form 4 on 20 June 2025. No 10b5-1 plan was indicated.
Investor takeaway: This appears to be a routine equity incentive award to align director interests with shareholders; the 20,000-share size is modest relative to Medicinova’s outstanding share count and therefore immaterial from a dilution standpoint.